Deans' stroke musings: Safe and Effective Vascular Endothelial Cell Growth Factor (VEGF)-based Therapeutic Angiogenesis for Ischemic Stroke: Insights from Preclinical Trials

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, July 1, 2013

Safe and Effective Vascular Endothelial Cell Growth Factor (VEGF)-based Therapeutic Angiogenesis for Ischemic Stroke: Insights from Preclinical Trials

Your doctor should be able to figure out some stroke protocols from this. Ask him/her if they'll be ready for your next stroke in 5 years? Thats a serious question.
http://link.springer.com/chapter/10.1007/978-90-481-9495-7_8

Abstract

A major problem facing ischemic stroke therapy is the lack of treatments that directly restore the anatomy and physiology of the injured neurovascular unit. Therapeutic angiogenesis emerged as a potential treatment for ischemic stroke after preclinical studies demonstrated that neovascularization induced by angiogenic pharmacological agents is associated with neuroprotection.

This chapter discusses the: (1) epidemiology of ischemic stroke and the limitations of current treatments, (2) neuroprotection and therapeutic angiogenesis as new treatments for ischemic stroke, (3) biology of vascular endothelial cell growth factor (VEGF) and how VEGF has become a prime candidate for therapeutic angiogenesis, (4) potential clinical benefits and adverse effects of VEGF-based therapeutic angiogenesis for ischemic stroke, and (5) gaps in knowledge requiring further preclinical investigations before VEGF-based therapeutic angiogenesis can be considered safe and effective to begin clinical trials for ischemic stroke patients.

The unresolved issues in the preclinical trials are whether: (A) VEGF-based therapeutic angiogenesis promotes or hinders neuroprotection, (B) doses of VEGF not demonstrating adverse effects at the light microscopy level associated with clinically-significant ultrastructural alterations of the neurovascular unit, (C) VEGF combination therapy provide greater neuroprotection over VEGF monotherapy without additional adverse effects, (D) different isoforms of VEGF produce different therapeutic outcomes, and how the most beneficial isoform affects the anatomy and physiology of other organs, (E) VEGF-based therapeutic angiogenesis affects systemic hemodynamics, (F) different animal models of ischemic stroke produce similar favorable or adverse outcomes, including the influences of age, gender and coexisting chronic diseases, (G) gene therapy and stem cells are beneficial for VEGF-based therapeutic angiogenesis for stroke.